Published in Rheumatology (Oxford) on April 06, 2017
Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health (2011) 5.12
Discrete choice experiments in health economics: a review of the literature. Health Econ (2010) 4.58
Conducting discrete choice experiments to inform healthcare decision making: a user's guide. Pharmacoeconomics (2008) 4.28
Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial. Am J Med (2011) 1.84
Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations. Health Econ (2011) 1.63
Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics (2014) 1.60
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
Sample Size Requirements for Discrete-Choice Experiments in Healthcare: a Practical Guide. Patient (2015) 1.34
Early assessment of medical technologies to inform product development and market access: a review of methods and applications. Appl Health Econ Health Policy (2011) 1.13
Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment. Arthritis Res Ther (2014) 1.11
Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis. Patient Prefer Adherence (2013) 1.11
Role of patient and public participation in health technology assessment and coverage decisions. Expert Rev Pharmacoecon Outcomes Res (2011) 1.02
Patient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysis. Osteoporos Int (2012) 0.98
The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy (2010) 0.95
The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health (2012) 0.93
Men's preferences for prostate cancer screening: a discrete choice experiment. Br J Cancer (2013) 0.91
The use of research evidence on patient preferences in health care decision-making: issues, controversies and moving forward. Expert Rev Pharmacoecon Outcomes Res (2014) 0.88
Reconceptualising the external validity of discrete choice experiments. Pharmacoeconomics (2014) 0.87
Empirical Testing of the External Validity of a Discrete Choice Experiment to Determine Preferred Treatment Option: The Case of Sleep Apnea. Health Econ (2014) 0.86
Public engagement in health technology assessment and coverage decisions: a study of experiences in France, Germany, and the United Kingdom. J Health Polit Policy Law (2012) 0.84
A Review of Patient Preferences for Osteoporosis Drug Treatment. Curr Rheumatol Rep (2015) 0.83
How important is mode of administration in treatments for rheumatic diseases and related conditions? Curr Rheumatol Rep (2015) 0.83
Using Discrete Choice Experiment to elicit patient preferences for osteoporosis drug treatments: where to from here? Arthritis Res Ther (2014) 0.81
Encounter Decision Aid vs. Clinical Decision Support or Usual Care to Support Patient-Centered Treatment Decisions in Osteoporosis: The Osteoporosis Choice Randomized Trial II. PLoS One (2015) 0.80
The development of a personalized patient education tool for decision making for postmenopausal women with osteoporosis. Osteoporos Int (2016) 0.78
Potential cost-effectiveness for using patient decision aids to guide osteoporosis treatment. Osteoporos Int (2016) 0.78
Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists. Ann Rheum Dis (2016) 0.77
Life Expectancy in Patients Treated for Osteoporosis: Observational Cohort Study Using National Danish Prescription Data. J Bone Miner Res (2015) 1.50
Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. J Clin Densitom (2016) 1.47
Public health impact and cost-effectiveness of dairy products supplemented with vitamin D in prevention of osteoporotic fractures. Arch Public Health (2015) 0.81
Self-reported walking speed: a useful marker of physical performance among community-dwelling older people? J Am Med Dir Assoc (2014) 0.81
A reference case for economic evaluations in osteoarthritis: an expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum (2014) 0.80
Association of early childhood abdominal circumference and weight gain with blood pressure at 36 months of age: secondary analysis of data from a prospective cohort study. BMJ Open (2014) 0.78
Discrete Choice Experiment Response Rates: A Meta-analysis. Health Econ (2016) 0.76
In Memoriam: Pierre J. Meunier. Calcif Tissue Int (2016) 0.75
Comment on: Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment: reply. Rheumatology (Oxford) (2017) 0.75
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol (2017) 0.75
Quantitative modelling of hip fracture trends in 14 European countries: testing variations of a shared reversal over time. Sci Rep (2017) 0.75